Explain the resolution criteria for Sanofi's Dupixent FDA approval for CSU in children in the simplest terms, highlighting the difference between a qualifying approval and a Complete Response Letter (CRL).

AI-powered analysis for: Explain the resolution criteria for Sanofi's Dupixent FDA approval for CSU in children in the simplest terms, highlighting the difference between a qualifying approval and a Complete Response Letter (CRL).. Get detailed insights and real-time data on PolyPredict AI.

Search for recent opinions from biotech analysts and medical KOLs regarding the FDA's upcoming decision on Sanofi's Dupixent for CSU in children, and summarize the bullish or bearish market sentiment.

AI-powered analysis for: Search for recent opinions from biotech analysts and medical KOLs regarding the FDA's upcoming decision on Sanofi's Dupixent for CSU in children, and summarize the bullish or bearish market sentiment.. Get detailed insights and real-time data on PolyPredict AI.

Given the FDA's expected decision date of April 27, 2026, calculate if the potential excess return on betting on this Dupixent approval justifies locking up capital until May, compared to risk-free yields in DeFi protocols.

AI-powered analysis for: Given the FDA's expected decision date of April 27, 2026, calculate if the potential excess return on betting on this Dupixent approval justifies locking up capital until May, compared to risk-free yields in DeFi protocols.. Get detailed insights and real-time data on PolyPredict AI.

FDA approves Sanofi's Dupixent?

Tech|$10.1k Vol|

3 days 9 hrs

FDA approves Sanofi's Dupixent? - AI Found +20¢ Mispricing

AI Signal Dashboard

Last updated: 04.22 12:02

Top Undervalued

+20¢

(No)

FDA approves Sanofi's Dupixent? AI analysis: • +20¢ undervalued • Live Prediction Market fair value & mispricing alerts.

Undervalued Options Insights:

Dupixent, co-developed by Sanofi and Regeneron, has robust clinical data in chronic spontaneous urti...

🔓 Log in to see more

All Outcomes

Market Price

AI Fair Value

Value Edge

YesNo

99.95¢

0.05¢

80¢

20¢

0¢

+20¢

⚠️ Risk Warning: Live data may lag! Prices can shift instantly due to news or low liquidity. Before trading, use AI Chat for [Live Recalculate], [Check Liquidity], [Trollbox Radar], or review [Fair Value Logic] to verify.

Hedging

SNY

REGN

Dupixent is a core blockbuster drug co-developed and commercialized by Sanofi (SNY) and Regeneron (REGN). Although pediatric CSU is just one sub-indication, the approval or rejection of new indications directly affects the drug's revenue ceiling and is capable of causing tradable volatility in the stock prices of these two pharmaceutical giants.

Movers

From April 21, 2026 to April 22, 2026, the price of Option_'Yes' surged from 46.5c to a peak of 83c, before slightly pulling back to 78.5c. This is likely due to increased market anticipation of an approval as the PDUFA date (April 27) approaches, or possibly driven by favorable insider information or positive analyst reports. Prior to this, no historical movement records were available. The price had been relatively stable at 46.5c over the past three days, reflecting an early wait-and-see attitude.